Updates in the management of polycythemia vera and essential thrombocythemia by Prithviraj Bose, Srdan Verstovsek

Get full text

MF management by Prithviraj Bose, Srdan Verstovsek

Get full text

JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives by Prithviraj Bose, Srdan Verstovsek

Get full text

Ruxolitinib for the treatment of myelofibrosis: its clinical potential by Ostojic A, Vrhovac R, Verstovsek S

Get full text

Ruxolitinib: a targeted treatment option for patients with polycythemia vera by Vaddi K, Verstovsek S, Kiladjian JJ

Get full text

Novel Therapies in Myeloproliferative Neoplasms: Beyond JAK Inhibitor Monotherapy by Sophia S. Lee, Srdan Verstovsek, Naveen Pemmaraju

Get full text

Momelotinib: an emerging treatment for myelofibrosis patients with anemia by Helen T. Chifotides, Prithviraj Bose, Srdan Verstovsek

Get full text

Association of Myelofibrosis Phenotypes with Clinical Manifestations, Molecular Profiles, and Treatments by Helen T. Chifotides, Srdan Verstovsek, Prithviraj Bose

Get full text

Novel Concepts of Treatment for Patients with Myelofibrosis and Related Neoplasms by Prithviraj Bose, Lucia Masarova, Srdan Verstovsek

Get full text

Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes by Mughal TI, Vaddi K, Sarlis NJ, Verstovsek S

Get full text

PB2232: A RANDOMIZED, CONTROLLED CLINICAL TRIAL (PHASE 2B) OF NS-018 VERSUS BEST AVAILABLE THERAPY IN SUBJECTS WITH PRIMARY OR SECONDARY MYELOFIBROSIS WITH SEVERE THROMBOCYTOPENIA by Melisa Palacio, Srdan Verstovsek, Tomonori Uno, Taishi Yamashita

Get full text

Splenomegaly in myelofibrosis—new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors by Randhawa Jasleen, Ostojic Alen, Vrhovac Radovan, Atallah Ehab, Verstovsek Srdan

Get full text

Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor by Singer J, Al-Fayoumi S, Ma H, Komrokji R, Mesa R, Verstovsek S

Get full text

Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety by Srdan Verstovsek, Ruben A. Mesa, Robert A. Livingston, Wilson Hu, John Mascarenhas

Get full text

Systemic Mastocytosis and Other Entities Involving Mast Cells: A Practical Review and Update by Siba El Hussein, Helen T. Chifotides, Joseph D. Khoury, Srdan Verstovsek, Beenu Thakral

Get full text

Practical management of patients with myelofibrosis receiving ruxolitinib. by Harrison, C, Mesa, R, Ross, D, Mead, A, Keohane, C, Gotlib, J, Verstovsek, S

Mpn-238 single-cell RNA profiling of myelofibrosis patients reveals pelabresib-induced decrease of megakaryocytic progenitors and normalization of CD4+ T cells in peripheral blood by Zavidij, O, Haradhvala, NJ, Meyer, R, Cui, J, Verstovsek, S, Oh, S, Mead, A, Taverna, P

Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies by Srdan Verstovsek, Olatoyosi Odenike, Jack W. Singer, Tanya Granston, Suliman Al-Fayoumi, H. Joachim Deeg

Get full text

P1043: OUTCOME OF PATIENTS WITH PREFIBROTIC MYELOFIBROSIS FROM A LARGE ACADEMIC CENTER by L. Masarova, P. Bose, N. Pemmaraju, H. Chifotides, L. Zhou, Z. Estrov, H. Kantarjian, S. Verstovsek

Get full text

S192: SINGLE-CELL RNA PROFILING OF MYELOFIBROSIS PATIENTS REVEALS PELABRESIB-INDUCED DECREASE OF MEGAKARYOCYTIC PROGENITORS AND NORMALIZATION OF CD4+ T CELLS IN PERIPHERAL BLOOD by O. Zavidij, N. J. Haradhvala, R. Meyer, J. Cui, S. Verstovsek, S. Oh, A. Mead, P. Taverna

Get full text